Tixagevimab and Cilgavimab
Class: Monoclonal Antibodies
- SARS-CoV-2-specific Monoclonal Antibody
- SARS-CoV-2 spike protein-directed attachment inhibitor
Brands: EvusheldTM
Warning
Special Alerts:
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that a combined regimen of Tixagevimab and Cilgavimab is not an approved treatment for coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, but rather, is being investigated for and is currently available under an FDA emergency use authorization (EUA) for the preexposure prophylaxis of COVID-19 in adults and pediatric individuals. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to the information contained in the accompanying monograph, and specifically disclaims all such warranties. Readers of this information are advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information contained in the monograph in any and all practice settings. Readers are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Introduction
Antiviral; recombinant human IgG1 neutralizing monoclonal antibodies specific for SARS-CoV-2 virus; used in a combination regimen.
Uses for Tixagevimab and Cilgavimab
Coronavirus Disease 2019 (COVID-19)
Being investigated for and has been used for prevention of coronavirus disease 2019† caused by SARS-CoV-2.
One of several SARS-CoV-2-specific monoclonal antibody regimens being evaluated for prevention of COVID-19.
Although efficacy and safety not definitely established, tixagevimab and cilgavimab is available under an FDA emergency use authorization (EUA) for preexposure prophylaxis of COVID-19 in certain individuals who are not expected to mount an adequate immune response to a complete COVID-19 vaccination series or for whom COVID-19 vaccination is not recommended.
On December 8, 2021, FDA issued an EUA that permits use of tixagevimab and cilgavimab for the preexposure prophylaxis (PrEP) of COVID-19 in adults and pediatric individuals ≥12 years of age weighing ≥40 kg who are not currently infected with SARS-CoV-2 and who have not.
